

1 Article

# 2 Immunogenicity following two doses of BBIBP-CorV vaccine 3 and a third booster dose with viral vector and mRNA 4 COVID-19 vaccines against delta and omicron variants in prime 5 immunized adults with two doses of BBIBP-CorV vaccine

6 Jira Chansaenroj<sup>1</sup>, Nungruthai Suntronwong<sup>1</sup>, Sitthichai Kanokudom<sup>1,2</sup>, Suvichada Assawakosri<sup>1,2</sup>, Ritthideach  
7 Yorsaeng<sup>1</sup>, Preeyaporn Vichaiwattana<sup>1</sup>, Sirapa Klinfueng<sup>1</sup>, Lakana Wongsrisang<sup>1</sup>, Donchida Srimuan<sup>1</sup>, Thaksaporn  
8 Thatsanatom<sup>1</sup>, Thanunrat Thongmee<sup>1</sup>, Chompoonut Auphimai<sup>1</sup>, Pomjarim Nilyanimit<sup>1</sup>, Nasamon Wanlapakorn<sup>1,3</sup>,  
9 Natthinee Sudhinaraset<sup>1</sup>, Yong Poovorawan<sup>1,4\*</sup>

10  
11  
12  
13  
14  
15  
16  
17  
18

<sup>1</sup> Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand; e-mail@e-mail.com

<sup>2</sup> Osteoarthritis and Musculoskeleton Research Unit, Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand; e-mail@e-mail.com

<sup>3</sup> Division of Academic Affairs, Faculty of Medicine, Chulalongkorn University; e-mail@e-mail.com

<sup>4</sup> The Royal Society of Thailand (FRS(T)), Sanam Sueapa, Dusit, Bangkok 10330, Thailand; e-mail@e-mail.com

\* Correspondence: Yong.P@chula.ac.th; Tel.: +662 256 4929

19  
20  
21  
22  
23  
24  
25

**Abstract:** Coronavirus disease 2019 (COVID-19) booster vaccination is being comprehensively evaluated globally due to waning immunity and the emergence of new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. Therefore, this study aimed to evaluate antibody responses in individuals vaccinated with two doses of BBIBP-CorV vaccine and to explore the boosting effect of the different vaccine platforms in BBIBP-CorV-primed healthy adults, including viral vector vaccine (AZD122) and mRNA vaccines (BNT162b2 and mRNA-1273). The results showed that, in the BBIBP-CorV prime group, the total receptor-binding domain (RBD) immunoglobulin (Ig) and anti-RBD IgG levels waned significantly at 3 months after receiving the second dose. However, after the booster, RBD-specific binding antibody levels increased. Neutralizing antibody measured by a surrogate neutralization test showed of inhibition over 90% against the SARS-CoV-2 delta variant but less than 70% against omicron variant after the third dose on day 28. All booster vaccines could induce the total IFN- $\gamma$  T-cell response. The reactogenicity was acceptable and well tolerated without serious adverse events. This study supported administration of the third dose with either viral vector or mRNA vaccine for the BBIBP-CorV-primed individuals to stimulate antibody and T cell responses.

**Keywords:** Third dose, Inactivated vaccine, BBIBP-CorV, viral vector vaccine, mRNA vaccine

**Citation:** Lastname, F.; Lastname, F.;  
Lastname, F. Title. *Vaccines* **2022**, *10*, 27  
x. <https://doi.org/10.3390/xxxxx>

Academic Editor: Firstname  
Lastname

Received: date  
Accepted: date  
Published: date

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Copyright:** © 2022 by the author  
Submitted for possible open access  
publication under the terms and  
conditions of the Creative Commons  
Attribution (CC BY) license  
(<https://creativecommons.org/licenses/by/4.0/>).

## 1. Introduction

The coronavirus disease 2019 (COVID-19) pandemic is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It can result in mild to severe illness leading to hospitalization and death [1]. Currently available COVID-19 vaccines have been effective for the control and prevention of COVID-19 outbreaks. During this pandemic, many COVID-19 vaccines have been approved by the World Health Organization (WHO) for emergency use and are effective against SARS-CoV-2 in adults [2,3]. To date, inactivated vaccine candidates have been reported to be generally safe and have induced

42  
43

44 antibody responses in adults in preclinical trials [4]. The BBIBP-CorV vaccine is a killed  
45 inactivated coronavirus vaccine prepared by  $\beta$ -propiolactone [5]. In May 2021, the  
46 BBIBP-CorV vaccine was the first Chinese vaccine granted approval by the WHO for  
47 emergency use. Clinical trials on the BBIBP-CorV vaccine showed that BBIBP-CorV could  
48 protect against SARS-CoV-2 infection. The average quantitative IgG anti-spike protein  
49 antibodies levels among the participants on day 18 after vaccination with the  
50 BBIBP-CorV vaccine with no previous SARS-CoV-2 infection history was 40 AU/mL [6].  
51 The most common reported adverse reactions of the BBIBP-CorV vaccine included mild  
52 pain at the injection site, fever, and fatigue [7]. Phase 3 clinical trials between July and  
53 December 2020 in seven countries have shown that two doses of the BBIBP-CorV vaccine  
54 had an efficacy of 78.1% against symptomatic cases, 100% protection against severe dis-  
55 ease, and a 99% rate of seroconversion [4]. However, the antibody titers waned over time  
56 and may not be adequate to protect against the omicron variant [4,8]. Therefore, the  
57 Centre for Disease Prevention and Control China recommended a booster dose for  
58 BBIBP-CorV-primed individuals to stimulate adequate protection against the newly  
59 emerged omicron variant [9].

60 Although the efficacy of the vaccine and the ability to induce immune responses in  
61 two-dose-immunized participants can induce robust immunity, breakthrough infection  
62 with COVID-19 has been reported worldwide [2,3]. Several studies have observed that  
63 the decline in immunity may be related to a variant virus, weakening of vaccine-induced  
64 immunity, neutralizing antibody titers, or the effectiveness of the vaccine against symp-  
65 tomatic illness gradually weakens over time [2,3,10,11]. A study evaluating two doses of  
66 BBIBP-CorV vaccine effectiveness against SARS-CoV-2 variants showed efficacies of  
67 39.2% for beta, 33.9% for delta, and 11.3% for alpha variants [12]. The emergence of the  
68 SARS-CoV-2 omicron variant (B.1.1.529), with several mutations recently identified in  
69 their spike, has become the predominant variant worldwide since November 2021 [13]. In  
70 the interim statement on December 16, 2021, the WHO recommended that viral vector or  
71 mRNA vaccines can be considered third doses in those who received inactivated vaccines  
72 for initial doses [14]. Studies from the United States have found an increased estimate of  
73 vaccine effectiveness against delta and omicron variants among adults who had received  
74 a third dose of mRNA vaccine compared with unvaccinated and those who received two  
75 doses [15,16].

76 The immunogenicity of COVID-19 booster vaccinations has been tested in a variety  
77 of situations with various vaccines. Both heterologous and homologous third booster  
78 shots had a significantly improved immune response [17-19]. A booster vaccination has  
79 significantly increased neutralization capacity against the SARS-CoV-2 variants, thus  
80 overcoming waning immunity, circulating of the SARS-CoV-2 variants, and significantly  
81 reducing the rates of confirmed infection and severe disease [20,21]. To improve im-  
82 munity and enhance resistance to variants, the third dose of COVID-19 vaccination is  
83 necessary.

84 Antibody and T cell responses against SARS-CoV-2 in two-dose  
85 BBIBP-CorV-primed individuals after the administration of the third dose of BNT162b2  
86 have achieved a significant increase in both humoral and T cell-mediated immune re-  
87 sponse [22]. The immunogenicity after a booster dose with viral vector or other mRNA  
88 vaccine (mRNA1273) in BBIBP-CorV-primed individuals is limited. This study aimed to  
89 determine the kinetic response of antibodies in a cohort participant who completed the  
90 BBIBP-CorV vaccine and explore the immunogenicity of third doses with BBIBP-CorV  
91 vaccine or a heterologous booster COVID-19 vaccination using the viral vector and  
92 mRNA vaccines. The results could provide an opportunity to improve the flexibility and  
93 reliability of vaccination programs in the face of the COVID-19 pandemic.

## 94 2. Materials and Methods

### 95 2.1 Study design and population study

96 This study was a prospective cohort study including two groups of participants.  
97 The first group consisted of individuals who consented to receive two doses of the  
98 BBIBP-CorV vaccine (referred to as the BBIBP-CorV primed group). The second group  
99 comprised individuals primed with the two-dose BBIBP-CorV vaccine who were en-  
100 rolled for the third booster (referred to as the third booster group). The binding and  
101 neutralizing antibody titer and the T cell response before and after the third dose of vac-  
102 cination were evaluated. The inclusion criteria were immunocompetent individuals (age:  
103  $\geq 18$  years) with no or well-controlled comorbidities and no previous SARS-CoV-2 infec-  
104 tion in the medical history.

105 The BBIBP-CorV primed group consists of 51 participants who received the  
106 BBIBP-CorV vaccine at Synphaet Srinagarindra Hospital, Bangkok, Thailand between  
107 June, and July 2021. Blood samples from this group were collected at four time-points,  
108 day 0 (before receiving the first dose), day  $30 \pm 7$  days (just before receiving the second  
109 dose), day  $60 \pm 7$  days after receiving the first dose, and day  $120 \pm 7$  after receiving the  
110 first dose.

111 The third booster group consisted of 144 participants who received two prime doses  
112 of BBIBP-CorV over  $6 \pm 1$  month and were enrolled to receive the third dose at the Center  
113 of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine,  
114 Chulalongkorn University. Participants were enrolled between November and December  
115 2021. This group was further divided into three sub-groups who were to receive the third  
116 booster dose (AZD1222, BNT162b2, or mRNA-1273). The third dose was administered  
117 according to vaccine availability. The participants and investigators were not blinded.  
118 The blood samples from this group were collected at four time points: before the third  
119 dose vaccination (day 0, baseline), and after receiving the booster dose (day  $14 \pm 7$  days,  
120 day  $28 \pm 7$  days, and day  $90 \pm 7$  days).

121 This study protocol was approved by the Institutional Review Board of the Faculty  
122 of Medicine of Chulalongkorn University (IRB numbers 192/64 and 546/64). Informed  
123 consent was obtained from all subjects involved in the study prior to enrollment in the  
124 study. All volunteers were informed about the details of the study prior to its start. The  
125 study was conducted in accordance with the Declaration of Helsinki and the Good Clin-  
126 ical Practice Guidelines (ICH-GCP).

### 127 2.2 Study vaccines interventions

128 BBIBP-CorV (Vero cell) (Sinopharm, National Biotec Group Co., Beijing Institute of  
129 Biological Products, China) is an inactivated virus vaccine developed from the whole  
130 SARS-CoV-2 strain HB02. The HB02 strain is obtained by passaging and purification in  
131 Vero cells. Consequently, the entire virion is inactivated in  $\beta$ -propiolactone and is further  
132 absorbed with aluminum hydroxide. One dose (0.5 mL) contains 6.50 U [5]. AZD1222  
133 (ChAdOx1-S/nCoV-19, University of Oxford/AstraZeneca, Oxford, UK) is a  
134 non-replicating chimpanzee adenovirus Oxford 1 vector vaccine presenting the  
135 SARS-CoV-2 spike protein. The virion is produced in genetically modified HEK293 cells.  
136 One dose (0.5 mL) contains  $5 \times 10^{10}$  infectious units [23]. BNT162b2 (Pfizer-BioNTech Inc.,  
137 New York, NY, USA) and mRNA-1273 (ModernaTX Inc., Cambridge, MA, USA) are  
138 modified RNA containing lipid nanoparticles encoding the full-length spike of  
139 SARS-CoV-2, modified by two proline mutations to lock it in the prefusion conformation.  
140 One dose contains 30 and 100  $\mu\text{g}$  for BNT162b2 and mRNA-1273, respectively [24,25].

141 After receiving the additional dose, all study participants were monitored for immuno-  
142 genicity and safety.

### 143 2.3 Monitoring of adverse events

144 Participants were informed of the name of the vaccine and were observed adverse  
145 events for at least 30 minutes after vaccination. All participants were continuously mon-  
146 itored for adverse events after immunization (AEFI) within 7 days after receiving the  
147 booster dose using self-assessment records via online or paper questionnaires. The ad-  
148 verse events contain system reactions and local reactions. System reactions included fe-  
149 ver, headache, myalgia, nausea, vomiting, diarrhea, joint pain, chills, and dizziness. Local  
150 reactions included pain at the injection site, swelling, and redness.

### 151 2.4 Laboratory Experiments

#### 152 2.4.1 Immunoglobulin assays

153 All serum samples were analyzed using SARS-CoV-2 total receptor binding domain  
154 immunoglobulin (total RBD Ig) and anti-RBD IgG by using the  
155 Electrochemiluminescence Immunoassay (ECLIA) (Roche Diagnostics GmbH, Mann-  
156 heim, Germany) and the chemiluminescent microparticle immunoassay (CMIA) (Abbott  
157 Diagnostics, Sligo, Ireland), respectively [26]. A total RBD Ig level of  $\geq 0.8$  U/mL was  
158 considered positive. The anti-RBD IgG level with a value  $\geq 7.1$  BAU/mL was considered  
159 positive.

#### 160 2.4.2 Surrogate virus neutralization test (sVNT)

161 To assess SARS-CoV-2 surrogate virus neutralization, the subset of serum samples  
162 from the third booster group at all time points were also evaluated for neutralizing ac-  
163 tivity against the SARS-CoV-2 variants of concern (VOCs), namely B.1.617.2 (delta) and  
164 B.1.1.529 (omicron), using an ELISA-based surrogate virus neutralization test (sVNT)  
165 based on antibody-mediated blockage of the interaction between viral receptor binding  
166 domain (RBD) and the angiotensin-converting enzyme 2 (ACE2) protein [27]. Further-  
167 more, a cPass™ SARS-CoV-2 neutralizing antibody detection kit (GenScript Biotech,  
168 Piscataway, NJ, USA) was used for all strains following the manufacturer's instructions.  
169 Recombinant RBDs from B.1.617.2 (containing L452R and T478K) and B.1.1.529 (con-  
170 taining N501Y, E484A, K417N, and D614G) were also used with this kit. The ability of a  
171 serum to inhibit binding between RBD and ACE2 was calculated as a percentage as fol-  
172 lows:  $1 - (\text{average OD of the sample} / \text{average OD of the negative control}) \times 100$ . A value  
173  $\geq 30\%$  was considered positive, indicating the presence of neutralizing antibodies. The  
174 lower limit of detection was established as 0% inhibition.

#### 175 2.4.3 SARS-CoV-2 Stimulating IFN- $\gamma$ Assay

176 The subset of participants' whole heparinized blood samples from the third booster  
177 group was taken at all time points on days 0, 14, 28, and 90 to assess the specific T-cell  
178 response. The heparinized whole blood sample was collected in a blood collection tube  
179 from QuantiFERON (QFN) SARS-CoV-2 RUO kit (QIAGEN, Hilden, Germany) follow-  
180 ing the manufacturer's instruction and incubated at 37°C for 21 to 24 hours and was then  
181 centrifuged for 15 minutes at 3500 g to harvest the plasma. This test is based on the *in*  
182 *vitro* stimulation of CD4<sup>+</sup> and CD8<sup>+</sup> lymphocytes in whole heparinized blood with a  
183 combination of specific SARS-CoV-2 antigens covering the S protein, followed by meas-  
184 urement in plasma of IFN- $\gamma$  production by ELISA. This assay consisted of two sets of  
185 SARS-CoV-2 S antigens. The Ag1 tube contained CD4<sup>+</sup> epitopes derived from the S1  
186 subunit (RBD), while the Ag2 tube contained CD4<sup>+</sup> and CD8<sup>+</sup> epitopes from S1 and S2.  
187 Furthermore, the plasma fraction was used to determine the concentration of IFN- $\gamma$

(IU/mL) using QuantiFERON® ELISA. Absorbance was measured at 450 nm and calculated using IFN- $\gamma$  standard curve using the QuantiFERON R&D Analysis Software. The seropositivity rate was calculated using IFN- $\gamma$  levels from the stimulated tube minus the negative control tube. An IFN- $\gamma$  level of  $\geq 0.15$  IU/mL and  $\geq 25\%$  of Nil were defined as a positive response against SARS-CoV-2, while the maximum limit was 10.0 IU/mL.


### 2.5 Statistical Analysis

The sample size was calculated using the G\*power software version 3.1.9.6. Graphical representation and statistical analyses were performed using GraphPad Prism version 7.0 for Microsoft Windows. Categorical analyses of age and sex were performed using the chi-square test and Welch’s ANOVA. IgG-specific RBDs were designated as geometric mean titers (GMT) with a 95% confidence interval (CI). Other parameters were presented as medians with interquartile ranges. Differences in antibody titers, percentage inhibition, and IU/mL minus nil between groups were calculated using the Kruskal–Wallis test or Wilcoxon signed rank test (nonparametric) multiple comparison adjustments. A *p*-value < 0.05 was considered to indicate statistical significance.

## 3. Results

### 3.1 Antibody responses against SARS-CoV-2 in the BBIBP-CorV primed group


The BBIBP-CorV primed group consisted of 21 male participants and 30 female participants. The average and median ages are 37.7 and 35.0, respectively. Ten participants were lost to follow-up during the study. The enrollment flow diagram is shown in Figure 1.



**Figure 1** Study diagram for enrollment of participants in this study. Schematic depicting a total of 51 participants in the BBIBP-CorV primed group and 144 participants in the third boost group.

Total levels of RBD Ig and anti-RBD IgG at 30 days after two-dose vaccination in the BBIBP-CorV primed group showed a seropositivity rate of 97.8% and 93.6%, respectively. The maximum level of total RBD Ig and anti-RBD IgG was detected in all participants after completing two doses of BBIBP-CorV at 30 days, with GMT 42.8 U/mL and 50.0 BAU/mL, respectively. The waning of antibody titers was observed after 90 days of completed vaccination, as shown in Figure 2 and Supplementary Table S1.

220



221

222

223

224

**Figure 2** Antibody responses against SARS-CoV-2 in the BBIBP-CorV primed group. **(a)** The total circulating RBD Ig of SARS-CoV-2 (U/mL), and **(b)** Circulating anti-RBD IgG of SARS-CoV-2 (BAU/mL). Lines represent GMTs. The dotted lines represent the cutoff titers;  $p < 0.01$  (\*\*).

225

### 3.2 Antibody responses against SARS-CoV-2 in the third booster group

226

227

228

229

230

231

232

233

234

235

236

237

In the third booster group, healthy participants who received two doses of BBIBP-CorV over  $6 \pm 1$  months were separated into three groups to receive the additional doses with a viral vector or mRNA COVID-19 vaccine depending on the vaccine availability. None of the 144 enrolled participants had underlying disease or had well-controlled disease, were not immunocompromised, or were receiving treatment with ongoing immunosuppressive therapy. The baseline demographic characteristics of all participants in the three groups, namely those who received vaccines AZD1222 ( $n = 33$ , median age = 45.0 years), BNT162b2 ( $n = 56$ , median age = 40.0 years), and mRNA-1273 ( $n = 55$ , median age = 46.0 years) vaccines; the average age of the participants enrolled in each group was 42.27, 41.89, and 44.02 years, respectively. There were no significant differences in sex and age in each group. The enrollment flow diagram is shown in Figure 1.

238

239

240

241

242

243

244

245


246

247

248

249

The most common symptom induced by the third booster dose of the COVID-19 vaccine in three groups was injection site pain. The requested injection site and systemic adverse reactions were reported. The most common adverse effects at the injection site and systemic adverse reactions were myalgias, headache, and chilling. The incidence of total local and systemic symptoms in the AZD1222, BNT162b2 and mRNA-1273 groups are shown in Figure 3 and Supplementary Table S1. The third dose of AZD1222 has a significantly lower incidence of swelling than BNT162b2, and the mRNA-1273 vaccine while fever symptoms have a higher incidence, the remaining differences were not significant. Any adverse reactions resolved within a few days. After vaccination, no severe adverse events (SAEs) were observed in all third booster subgroups.



250

251

252

253

254

255

256

257

**Figure 3** Reactogenicity of a booster dose of SARS-CoV-2 vaccines within 7 days after vaccination. Third booster subgroups: (a) AZD1222, (b) BNT162b2, and (c) mRNA-1273. The percentages of participants who recorded local, systemic, and adverse events are shown on the Y-axis. Fever was defined as mild: 38.0°C to < 38.5°C; moderate: 38.5°C to < 39.0°C; severe  $\geq$  39.0°C. For local and systemic symptoms, the classification was classified as mild: easily tolerated with no limitation of regular activity; moderate: some limitation of daily activity; severe: unable to perform regular daily activity.

258

259

260

261


262

263

264

The antibody level before the booster in individuals from all third booster subgroups showed that the total RBD Ig and anti-RBD IgG levels at baseline were maintained at a low level, similar to the BBIBP-CorV primed group. After receiving the third dose, there was a substantial increase in the highest titers on day 14 and a slight decrease up to day 90, as shown in Figure 4 and Supplementary Table S1. Compared with the third booster group, AZD1222 achieved total RBD Ig and anti-RBD IgG levels that were significantly lower than those achieved with BNT162b2 or mRNA-1273.

265




**Figure 4** Antibody responses to the SARS-CoV-2 assay in a third boost group. **(a)** The total RBD Ig circulating of SARS-CoV-2 (U/mL) and **(b)** The anti-RBD IgG circulating of SARS-CoV-2 (BAU/mL). Serum samples were obtained from participants who received the third dose with AZD1222 (green), BNT162b2 (red) or mRNA-1273 (blue). Lines represent GMTs (95% CI). The dotted lines represent the cutoff titers;  $p < 0.01$  (\*\*).

### 3.3 Surrogate virus neutralization test

The functionally binding antibody that may inhibit SARS-CoV-2 delta and omicron variants was evaluated by sVNT. According to Figure 5 and Supplementary Table S1, before the third dose vaccination, the median percentage of inhibition of participants who received BBIBP-CorV was less than 30.0% for the delta and omicron variants. In the comparison of neutralizing activities between the different third-dose platforms, the percentage inhibition against delta and omicron variants was achieved to the highest after booster on day 14. The median of neutralizing activities against the delta variant showed a 97.0% inhibition in the vaccination with the three vaccines studied. The median neutralizing activities against the omicron variant of the third dose with AZD1222, BNT162b2, and mRNA-1273 was a 49.8%, 67.4%, and 53.7%, respectively. On day 28, the percentage of inhibition against omicron variants decreased slightly to less than 30.0% on day 90, while the percentage of inhibition against delta variants was still higher than 90%. The neutralizing capacity of sera against the omicron variant in all third dose groups was lower than that of the delta variant. In addition, the third dose of AZD1222 vaccine recipients had no significant difference on the neutralizing activity against the delta variant with BNT162b2 and mRNA-1273 vaccine recipients but had a lower neutralizing activity against the omicron variant significantly ( $p$ -value  $< 0.01$ ).

The correlation was plotted between the percentage of inhibition against the SARS-CoV-2 variants, total-RBD Ig, and anti-RBD IgG. The nonlinear regression, one-phase decay model, can predict immunogenicity titers to neutralize inhibition against delta and omicron variants in the third dose with the different platforms (Supplementary Figures S1 and S2).






**Figure 5** Neutralization activities against SARS-CoV-2 variants B.1.617.2 (delta) and B.1.1.529 (omicron) measured by the Surrogate virus neutralization test (sVNT). The subset of serum samples was obtained from a third booster group. Participants who received the third dose of AZD1222 (green), BNT162b2 (red), or mRNA-1273 (blue) were selected to test sVNT at baseline, 14-, 28- and 90-days after the booster dose. **(a)** Neutralizing activity against delta variants, and **(b)** neutralizing activity against omicron variants. The lines represent medians with interquartile ranges (IQR). The dotted lines represent the cutoff titers;  $p$ -value < 0.01 (\*\*).

### 3.4 SARS-CoV-2 Stimulating IFN- $\gamma$ CD4+/IFN- $\gamma$ CD4+ and CD8+ T-cell response

The IFN- $\gamma$  response to SARS-CoV-2 IFN- $\gamma$  CD4+/IFN- $\gamma$  CD4+ and CD8+ were evaluated, as shown in Figure 6 and Supplementary Table S1. Interestingly, a potential antiviral-induced IFN- $\gamma$  stimulation of T cells was notably observed. The marked individual difference in terms of IFN- $\gamma$  release induced by IFN- $\gamma$  CD4+/IFN- $\gamma$  CD4+ and CD8+ ranged from 0.0 IU/mL to 10.0 IU/mL. In terms of the serological response, the seropositivity rates for the IFN- $\gamma$  CD4+/IFN- $\gamma$  CD4+ and CD8+ levels observed in most participants after the booster dose 14 days were 67.9%/82.1% for AZD1222, 83.3%/93.3% for BNT162b2, and 86.2%/93.1% for mRNA-1273. The production of IFN- $\gamma$  by T-cells was decreased on days 28 and 90, consistent with the total RBD Ig and anti-RBD IgG levels. All booster vaccines showed that humoral immunity also developed cellular immunity. In contrast, both BNT162b2 and mRNA-1273 vaccines can stimulate robust antigen-specific T-cell responses after 14 days with especially high levels of IFN- $\gamma$ . There was a good correlation between the results for IFN- $\gamma$  CD4+/IFN- $\gamma$  CD4+ and CD8+ (Spearman correlation coefficient,  $p$ -value < 0.01).



**Figure 6 SARS-CoV-2-stimulating IFN- $\gamma$  assay.** The subset of heparinized samples was obtained from a third booster group. Participants who received the third dose of AZD1222 (green), the BNT162b2 (red), or the mRNA-1273 (blue) were stimulated by CD4+ epitope derived from RBD (Ag1), and CD4+/CD8+ epitope derived from S1 and S2 subunits (Ag2) and incubated in a QFN blood collection tube for at least 21 hours. QFN IFN- $\gamma$  ELISA evaluated the plasma fraction on days 0, 14, 28, and 90. **(a)** The IFN- $\gamma$  produced by CD4+ specific Ag1, and **(b)** The IFN- $\gamma$  produced by CD4+ and CD8+ specific Ag2. Lines represent medians (IQR). The dotted lines represent cutoff titers. Statistical analysis was performed using the Wilcoxon signed-rank test (two-tailed); p-value < 0.05 (\*).

#### 4. Discussion

The BBIBP-CorV vaccine is a highly valuable tool against COVID-19, due to its less stringent storage and shipment requirements, which differs from mRNA-based vaccines. The BBIBP-CorV vaccine has been approved for use in more than 45 countries around the world, and the interim results of the phase 3 trials indicated a 78.1% efficacy in preventing the ancestral variant [28]. Our data showed that immunogenicity could be detected after two doses of the BBIBP-CorV vaccine at 30 days, and the seropositivity rate of total RBD Ig and anti-RBD IgG was 97.8% and 93.6%, respectively. The magnitudes of the total RBD Ig and anti-RBD IgG responses were highest (GMT 42.8 U/mL, and 50.0 BAU/mL, respectively) in individuals 30 days after having completed two doses of BBIBP-CorV vaccine and slightly decreased and maintain at a low level until 90 days to similar levels as the baseline of the third dose group who received over 6  $\pm$  1 months of two doses of BBIBP-CorV vaccine. These results were in line with a previous study reporting that on day 18 after vaccination with the BBIBP-CorV vaccine, more than half of the participants showed negative results for the IgG anti-spike protein antibody test and indicates that the BBIBP-CorV vaccine does not produce a sufficient immune response in most vaccinated individuals [6].

With regard to the side effects of the third dose, the previous studies [29,30] showed that the most reported adverse effects of AZD1222 were pain and tenderness at the injection site, fatigue, and headache. Side effects started on the first day after vaccination and lasted 1 to 3 days, while the most common side effects for BNT162b2 and mRNA-1273 were pain at the injection site, headaches, fever, flu-like symptoms and fatigue. Although postvaccination side effects are the same for all vaccines, the number and severity of these side effects differ significantly according to the type of vaccine. In this study, an incidence rate of injection site and systemic reactions was reported within 7 days after boost vaccination, all adverse symptoms were mild in severity and mostly

359 transient. The results suggest that a third booster vaccination in healthy adults aged over  
360 18 years is safe, and these results may help support booster vaccination strategies to be  
361 administered in the future [31].

362 Studies of the third dose of COVID-19 vaccination reported the effectiveness of re-  
363 ducing risk in symptomatic infection and hospitalization rates compared to two doses of  
364 vaccination [15,19,22]. Therefore, for the general population, vaccination is necessary.  
365 Furthermore, heterologous booster doses (two prime doses with inactivate or viral vector  
366 vaccine and the third dose with mRNA vaccine) appear to induce higher levels of im-  
367 mune response than homologous booster doses, suggesting that heterologous immu-  
368 nization could be considered an alternative to homologous booster doses for immuniza-  
369 tion programs [22,32,33]. To assess the immunogenicity of a booster vaccination, our  
370 study found that a third booster dose with heterologous booster immunization of  
371 AZD1222, BNT162b2, and mRNA-1273 showed a high titer of total RBD Ig and anti-RBD  
372 IgG compared to before the third booster. Immunogenicity and neutralizing antibody  
373 titers increased significantly on day 14. After 28 days from the third booster dose, the  
374 immunogenicity, and neutralizing titers continuously decreased until day 90. In correla-  
375 tion with previous studies, after previous priming vaccination with two doses of  
376 CoronaVac, the effectiveness against delta and omicron variants of a third booster shot of  
377 CoronaVac, AZD1222, and BNT162b2 14 days after vaccination was 56–80%, 56–90% and  
378 56–93%, respectively [14,34]. Neutralizing antibodies are the most important parameter  
379 for measuring the immune response to prevent disease and reinfections. Although neu-  
380 tralizing antibodies are difficult to investigate in routine laboratories, the level of an-  
381 ti-SARS-CoV-2 IgG is indicative. Previous studies found that neutralizing antibodies and  
382 anti-SARS-CoV-2 IgG titers are compatible. The level of total anti-RBD antibodies was  
383 strongly correlated with the neutralizing antibodies titers of SARS-CoV-2, especially  
384 against the ancestral strain [35,36]. This study showed that the titers of total RBD Ig and  
385 anti-RBD IgG are correlated with the neutralizing antibody titers against delta and omi-  
386 cron variants. Such results supported the concept that a higher immune response would  
387 provide better neutralizing antibodies in the real world.

388 For the IFN- $\gamma$  response, previous studies have reported that the third dose of inac-  
389 tivated SARS-CoV-2 vaccine could generate SARS-CoV-2 specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells  
390 and elicit B cell responses by antibody evolution [37]. This study observed seropositivity  
391 rates for the IFN- $\gamma$  CD4<sup>+</sup>/IFN- $\gamma$  CD4<sup>+</sup> and CD8<sup>+</sup> levels in most participants after the  
392 booster dose of 14 days, and a significant decrease in IFN- $\gamma$  production T cells after  
393 boosting the dose for 14 days, limiting the efficacy of the vaccines. This result is similar to  
394 that of a previous report [37] and suggests that a second dose is developing an effective  
395 immune response and further boosters may be needed to increase and retain the effec-  
396 tiveness of the vaccine in adults. Whether enhanced B and T cell responses could lead to  
397 greater protection efficacy is one of the key questions concerning current boosting strat-  
398 egies. As a result, a third dose of the vaccine after six months, even a viral vector or  
399 mRNA vaccine, has published new guidelines making it mandatory to get a booster.  
400 However, to generalize for a larger population, more data are needed in the future.

401 The limitations of the current study include the limit of detection of the sVNT assay.  
402 Most individuals receiving a booster dose achieved an elevation in antibody levels that  
403 was greater than the upper limit of detection. This method may not reflect the actual  
404 neutralizing antibody level. Furthermore, the lost follow-up participants due to break-  
405 through infection or lost contact during the follow-up period may not reflect the actual  
406 values at each time point.

407 In conclusion, a third dose heterologous regimen, two initial doses of BBIBP-CorV  
408 vaccines followed by a viral vector or mRNA vaccine induced a robust immunological

409 response. This study found that a two-dose schedule generated good immune memory.  
410 However, immunogenicity titers decreased to near or below the lower limit of the  
411 seropositivity rate over time. A third dose is given over  $6 \pm 1$  month after the second dose  
412 of BBIBP-CorV was highly effective in re-calling a specific SARS-CoV-2 immune re-  
413 sponse, leading to a significant rebound in antibody levels. This approach would make it  
414 possible to optimize the third available booster dose of vaccines without increasing the  
415 risk of infection and allowing a faster expansion of vaccination coverage.

416  
417 **Supplementary Materials:** The following supporting information can be downloaded at:  
418 [www.mdpi.com/xxx/s1](http://www.mdpi.com/xxx/s1)

419 Figure S1: Correlation between the percentage of inhibition against the SARS-CoV-2 variants and  
420 the total RBD Ig levels. The subset of serum samples was obtained from a third booster group.  
421 Participants who received the third dose of AZD1222 (green), BNT162b2 (red), or mRNA-1273  
422 (blue) were plotted with a non-linear regression curve. (a) AZD1222 against the delta variant, (b)  
423 AZD1222 against the omicron variant (c) BNT162b2 against the delta variant, (d) BNT162b2 against  
424 the omicron variant, (e) mRNA-1273 against the delta variant and (f) mRNA-1273 against the  
425 omicron variant.

426 **Figure S2** The correlation between the percentage of inhibition against SARS-CoV-2 variants and  
427 anti-RBD IgG levels. The subset of serum samples was obtained from a third booster group. Par-  
428 ticipants who received the third dose of AZD1222 (green), BNT162b2 (red), or mRNA-1273 (blue)  
429 were plotted with a non-linear regression curve. (a) AZD1222 against delta variant, (b) AZD1222  
430 against the omicron variant, (c) BNT162b2 against the delta variant, (d) BNT162b2 against the  
431 omicron variant, (e) mRNA-1273 against the delta variant, (f) mRNA-1273 against the omicron  
432 variant.

433 **Table S1** The demographic characteristics and laboratory tests value of participants enrolled in this  
434 study.

435  
436 **Author Contributions:** Conceptualization, J.C., N.S., S.K., S.A., R.Y., P.N., N.W., N.S., and Y.P.;  
437 Methodology, J.C., N.S., S.K., S.A., R.Y., P.V., S.K., L.W., D.S., T.T., T.T., C.A.; Software, J.C., N.S.,  
438 S.K., S.A., R.Y.; Validation, N.W., N.S.; Formal analysis, J.C., N.S., S.K., S.A.; Investigation, J.C.,  
439 N.S., S.K., S.A., R.Y.; Resources, N.W., N.S., and Y.P.; Data curation, J.C., S.K.; Writing original draft  
440 preparation, J.C.; Writing review and editing, J.C., N.W., and Y.P.; Visualization, J.C., N.S., S.K.;  
441 Supervision, N.S., and Y.P.; Project administration, P.N., D.S., T.T.; Funding acquisition, Y.P. All  
442 authors have read and agreed to the published version of the manuscript.

443 **Funding:** This research was funded by a Health Systems Research Institute (HSRI), the National  
444 Research Council of Thailand (NRCT), the Center of Excellence in Clinical Virology of  
445 Chulalongkorn University/King Chulalongkorn Memorial Hospital (GCE 59-009-30-005), the Se-  
446 cond Century Fund (C2F), Chulalongkorn University to Jira Chansaenroj and MK Restaurant  
447 Group Public Company

448 **Institutional Review Board Statement:** The study was conducted in accordance with the Declara-  
449 tion of Helsinki and approved by the Institutional Review Board of the Faculty of Medicine of  
450 Chulalongkorn University (IRB numbers 192/64, approval date 18 March 2021 and 546/64, approval  
451 date 20 July 2021).

452 **Informed Consent Statement:** Informed consent was obtained from all subjects involved in the  
453 study. Written informed consent has been obtained from the patients to publish this paper

454 **Data Availability Statement.** The authors confirm that the data supporting the findings of this  
455 study are available within the article.

456 **Acknowledgments:** We greatly appreciate all participants for helping and supporting this study.  
457 We thank all staff from the Center of Excellence in Clinical Virology, Faculty of Medicine,

458 Chulalongkorn University, for their help with the experiment. We also thank the Ministry of Public  
459 Health and Chulabhorn Royal Academy for providing the vaccines for this study.

460 **Conflicts of Interest:** The authors declare no conflict of interest.

461

## 462 References

- 463 1. Weiss, P.; Murdoch, D.R. Clinical course and mortality risk of severe COVID-19. *Lancet* **2020**, *395*, 1014-1015,  
464 doi:10.1016/S0140-6736(20)30633-4.
- 465 2. Del Rio, C.; Malani, P.N.; Omer, S.B. Confronting the Delta Variant of SARS-CoV-2, Summer 2021. *JAMA* **2021**, *326*, 1001-1002,  
466 doi:10.1001/jama.2021.14811.
- 467 3. Mallapaty, S. China's COVID vaccines have been crucial - now immunity is waning. *Nature* **2021**, *598*, 398-399, doi:10.1038/d41586-021-02796-w.
- 468 4. Al Kaabi, N.; Zhang, Y.; Xia, S.; Yang, Y.; Al Qahtani, M.M.; Abdulrazzaq, N.; Al Nusair, M.; Hassany, M.; Jawad, J.S.; Abdalla, J.; et al. Effect of 2  
469 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial. *JAMA* **2021**, *326*, 35-45,  
470 doi:10.1001/jama.2021.8565.
- 471 5. Wang, H.; Zhang, Y.; Huang, B.; Deng, W.; Quan, Y.; Wang, W.; Xu, W.; Zhao, Y.; Li, N.; Zhang, J.; et al. Development of an Inactivated Vaccine  
472 Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2. *Cell* **2020**, *182*, 713-721 e719, doi:10.1016/j.cell.2020.06.008.
- 473 6. Elgendy, M.O.; El-Gendy, A.O.; Alzarea, A.I.; Mahmoud, S.; Alqahtani, S.S.; Fahmy, A.M.; El-Seedi, H.R.; Sayed, A.M.; Alatawi, A.D.;  
474 Abdelrahim, M.E.A.; et al. SARS-CoV-2 Post Vaccinated Adverse Effects and Efficacy in the Egyptian Population. *Vaccines (Basel)* **2021**, *10*,  
475 doi:10.3390/vaccines10010018.
- 476 7. Xia, S.; Zhang, Y.; Wang, Y.; Wang, H.; Yang, Y.; Gao, G.F.; Tan, W.; Wu, G.; Xu, M.; Lou, Z.; et al. Safety and immunogenicity of an inactivated  
477 SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. *Lancet Infect Dis* **2021**, *21*, 39-51,  
478 doi:10.1016/S1473-3099(20)30831-8.
- 479 8. Sreepadmanabh, M.; Sahu, A.K.; Chande, A. COVID-19: Advances in diagnostic tools, treatment strategies, and vaccine development. *J Biosci*  
480 **2020**, *45*.
- 481 9. Elgendy, M.O.; Abdelrahim, M.E.A. Public awareness about coronavirus vaccine, vaccine acceptance, and hesitancy. *J Med Virol* **2021**, *93*,  
482 6535-6543, doi:10.1002/jmv.27199.
- 483 10. Chemaitelly, H.; Tang, P.; Hasan, M.R.; AlMukdad, S.; Yassine, H.M.; Benslimane, F.M.; Al Khatib, H.A.; Coyle, P.; Ayoub, H.H.; Al  
484 Kanaani, Z.; et al. Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. *N Engl J Med* **2021**, *385*, e83,  
485 doi:10.1056/NEJMoa2114114.
- 486 11. Madhi, S.A.; Baillie, V.; Cutland, C.L.; Voysey, M.; Koen, A.L.; Fairlie, L.; Padayachee, S.D.; Dheda, K.; Barnabas, S.L.; Bhorat, Q.E.; et al.  
487 Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. *N Engl J Med* **2021**, *384*, 1885-1898, doi:10.1056/NEJMoa2102214.
- 488 12. Ismail AlHosani, F.; Eduardo Stanciole, A.; Aden, B.; Timoshkin, A.; Najim, O.; Abbas Zaher, W.; AlSayedSaleh AlDhaheeri, F.; Al Mazrouie,  
489 S.; Rizvi, T.A.; Mustafa, F. Impact of the Sinopharm's BBIBP-CorV vaccine in preventing hospital admissions and death in infected vaccinees: Re-  
490 sults from a retrospective study in the emirate of Abu Dhabi, United Arab Emirates (UAE). *Vaccine* **2022**, *40*, 2003-2010,  
491 doi:10.1016/j.vaccine.2022.02.039.
- 492 13. Guo, Y.; Han, J.; Zhang, Y.; He, J.; Yu, W.; Zhang, X.; Wu, J.; Zhang, S.; Kong, Y.; Guo, Y.; et al. SARS-CoV-2 Omicron Variant: Epidemiolog-  
493 ical Features, Biological Characteristics, and Clinical Significance. *Front Immunol* **2022**, *13*, 877101, doi:10.3389/fimmu.2022.877101.
- 494 14. Costa Clemens, S.A.; Weckx, L.; Clemens, R.; Almeida Mendes, A.V.; Ramos Souza, A.; Silveira, M.B.V.; da Guarda, S.N.F.; de Nobrega,  
495 M.M.; de Moraes Pinto, M.I.; Gonzalez, I.G.S.; et al. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two  
496 doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. *Lancet* **2022**, *399*, 521-529,  
497 doi:10.1016/S0140-6736(22)00094-0.
- 498 15. Accorsi, E.K.; Britton, A.; Fleming-Dutra, K.E.; Smith, Z.R.; Shang, N.; Derado, G.; Miller, J.; Schrag, S.J.; Verani, J.R. Association Between 3  
499 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. *JAMA* **2022**, *327*,  
500 639-651, doi:10.1001/jama.2022.0470.


- 501 16. Thompson, M.G.; Natarajan, K.; Irving, S.A.; Rowley, E.A.; Griggs, E.P.; Gaglani, M.; Klein, N.P.; Grannis, S.J.; DeSilva, M.B.; Stenehjem, E.;  
502 et al. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and  
503 Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January  
504 2022. *MMWR Morb Mortal Wkly Rep* **2022**, *71*, 139-145, doi:10.15585/mmwr.mm7104e3.
- 505 17. Guo, W.; Duan, K.; Zhang, Y.; Yuan, Z.; Zhang, Y.B.; Wang, Z.; Zhao, D.; Zhang, H.; Xie, Z.; Li, X.; et al. Safety and immunogenicity of an  
506 inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: A randomized, double-blind, placebo-controlled, phase 1/2 trial.  
507 *EClinicalMedicine* **2021**, *38*, 101010, doi:10.1016/j.eclinm.2021.101010.
- 508 18. Zhu, F.; Jin, P.; Zhu, T.; Wang, W.; Ye, H.; Pan, H.; Hou, L.; Li, J.; Wang, X.; Wu, S.; et al. Safety and immunogenicity of a recombinant ade-  
509 novirus type-5-vectored COVID-19 vaccine with a homologous prime-boost regimen in healthy participants aged 6 years and above: a random-  
510 ised, double-blind, placebo-controlled, phase 2b trial. *Clin Infect Dis* **2021**, doi:10.1093/cid/ciab845.
- 511 19. Zuo, F.; Abolhassani, H.; Du, L.; Piralla, A.; Bertoglio, F.; de Campos-Mata, L.; Wan, H.; Schubert, M.; Cassaniti, I.; Wang, Y.; et al. Heterolo-  
512 gous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant. *Nat*  
513 *Commun* **2022**, *13*, 2670, doi:10.1038/s41467-022-30340-5.
- 514 20. Abu-Raddad, L.J.; Chemaitelly, H.; Ayoub, H.H.; Yassine, H.M.; Benslimane, F.M.; Al Khatib, H.A.; Tang, P.; Hasan, M.R.; Coyle, P.; Al  
515 Kanaani, Z.; et al. Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar. *JAMA*  
516 **2021**, *326*, 1930-1939, doi:10.1001/jama.2021.19623.
- 517 21. Bar-On, Y.M.; Goldberg, Y.; Mandel, M.; Bodenheimer, O.; Freedman, L.; Kalkstein, N.; Mizrahi, B.; Alroy-Preis, S.; Ash, N.; Milo, R.; et al.  
518 Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel. *N Engl J Med* **2021**, *385*, 1393-1400, doi:10.1056/NEJMoa2114255.
- 519 22. Matula, Z.; Gonczi, M.; Beko, G.; Kadar, B.; Ajzner, E.; Uher, F.; Valyi-Nagy, I. Antibody and T Cell Responses against SARS-CoV-2 Elicited  
520 by the Third Dose of BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) Vaccines Using a Homologous or Heterologous Booster Vac-  
521 cination Strategy. *Vaccines (Basel)* **2022**, *10*, doi:10.3390/vaccines10040539.
- 522 23. Falsey, A.R.; Sobieszczyk, M.E.; Hirsch, I.; Sproule, S.; Robb, M.L.; Corey, L.; Neuzil, K.M.; Hahn, W.; Hunt, J.; Mulligan, M.J.; et al. Phase 3  
523 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. *N Engl J Med* **2021**, *385*, 2348-2360, doi:10.1056/NEJMoa2105290.
- 524 24. Jackson, L.A.; Anderson, E.J.; Roupael, N.G.; Roberts, P.C.; Makhene, M.; Coler, R.N.; McCullough, M.P.; Chappell, J.D.; Denison, M.R.;  
525 Stevens, L.J.; et al. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. *N Engl J Med* **2020**, *383*, 1920-1931, doi:10.1056/NEJMoa2022483.
- 526 25. Polack, F.P.; Thomas, S.J.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.; Perez, J.L.; Perez Marc, G.; Moreira, E.D.; Zerbini, C.; et al.  
527 Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med* **2020**, *383*, 2603-2615, doi:10.1056/NEJMoa2034577.
- 528 26. Yorsaeng, R.; Suntronwong, N.; Phowatthanasathian, H.; Assawakosri, S.; Kanokudom, S.; Thongmee, T.; Vichaiwattana, P.; Auphimai, C.;  
529 Wongsrisang, L.; Srimuan, D.; et al. Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vac-  
530 cines in healthy adults. *Vaccine* **2022**, *40*, 524-530, doi:10.1016/j.vaccine.2021.11.083.
- 531 27. Tan, C.W.; Chia, W.N.; Qin, X.; Liu, P.; Chen, M.I.; Tiu, C.; Hu, Z.; Chen, V.C.; Young, B.E.; Sia, W.R.; et al. A SARS-CoV-2 surrogate virus  
532 neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. *Nat Biotechnol* **2020**, *38*, 1073-1078,  
533 doi:10.1038/s41587-020-0631-z.
- 534 28. Cheng, Z.J.; Huang, H.; Zheng, P.; Xue, M.; Ma, J.; Zhan, Z.; Gan, H.; Zeng, Y.; Lin, R.; Li, S.; et al. Humoral immune response of BBIBP  
535 COVID-19 vaccination before and after the booster immunization. *Allergy* **2022**, doi:10.1111/all.15271.
- 536 29. El-Shitany, N.A.; Harakeh, S.; Badr-Eldin, S.M.; Bagher, A.M.; Eid, B.; Almkadi, H.; Alghamdi, B.S.; Alahmadi, A.A.; Hassan, N.A.; Sindi,  
537 N.; et al. Minor to Moderate Side Effects of Pfizer-BioNTech COVID-19 Vaccine Among Saudi Residents: A Retrospective Cross-Sectional Study.  
538 *Int J Gen Med* **2021**, *14*, 1389-1401, doi:10.2147/IJGM.S310497.
- 539 30. Solomon, Y.; Eshete, T.; Mekasha, B.; Assefa, W. COVID-19 Vaccine: Side Effects After the First Dose of the Oxford AstraZeneca Vaccine  
540 Among Health Professionals in Low-Income Country: Ethiopia. *J Multidiscip Healthc* **2021**, *14*, 2577-2585, doi:10.2147/JMDH.S331140.

- 541 31. Hatmal, M.M.; Al-Hatamleh, M.A.I.; Olaimat, A.N.; Hatmal, M.; Alhaj-Qasem, D.M.; Olaimat, T.M.; Mohamud, R. Side Effects and Percep-  
542 tions Following COVID-19 Vaccination in Jordan: A Randomized, Cross-Sectional Study Implementing Machine Learning for Predicting Severity  
543 of Side Effects. *Vaccines (Basel)* **2021**, *9*, doi:10.3390/vaccines9060556.
- 544 32. Barros-Martins, J.; Hammerschmidt, S.I.; Cossmann, A.; Odak, I.; Stankov, M.V.; Morillas Ramos, G.; Dopfer-Jablonka, A.; Heidemann, A.;  
545 Ritter, C.; Friedrichsen, M.; et al. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1  
546 nCoV-19/BNT162b2 vaccination. *Nat Med* **2021**, *27*, 1525-1529, doi:10.1038/s41591-021-01449-9.
- 547 33. Borobia, A.M.; Carcas, A.J.; Perez-Olmeda, M.; Castano, L.; Bertran, M.J.; Garcia-Perez, J.; Campins, M.; Portoles, A.; Gonzalez-Perez, M.;  
548 Garcia Morales, M.T.; et al. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multi-  
549 centre, open-label, randomised, controlled, phase 2 trial. *Lancet* **2021**, *398*, 121-130, doi:10.1016/S0140-6736(21)01420-3.
- 550 34. Ai, J.; Zhang, Y.; Zhang, H.; Zhang, Q.; Fu, Z.; Lin, K.; Song, J.; Zhao, Y.; Fan, M.; Wang, H.; et al. Safety and immunogenicity of a third-dose  
551 homologous BBIBP-CorV boosting vaccination: interim results from a prospective open-label study. *Emerg Microbes Infect* **2022**, *11*, 639-647,  
552 doi:10.1080/22221751.2022.2025746.
- 553 35. Kaygusuz, S.; Korukluoglu, G.; Cosgun, Y.; Sahin, O.; Arslan, F. Investigation and long-term monitoring of the presence of neutralizing an-  
554 tibody in patients with COVID-19 disease of different clinical severity. *J Med Virol* **2022**, doi:10.1002/jmv.27751.
- 555 36. Sanchez-Sendra, B.; Albert, E.; Zulaica, J.; Torres, I.; Gimenez, E.; Botija, P.; Beltran, M.J.; Rodado, C.; Geller, R.; Navarro, D. Neutralizing  
556 antibodies against SARS-CoV-2 variants of concern elicited by the comirnaty COVID-19 vaccine in nursing home residents. *Sci Rep* **2022**, *12*, 3788,  
557 doi:10.1038/s41598-022-07849-2.
- 558 37. Liu, Y.; Zeng, Q.; Deng, C.; Li, M.; Li, L.; Liu, D.; Liu, M.; Ruan, X.; Mei, J.; Mo, R.; et al. Robust induction of B cell and T cell responses by a  
559 third dose of inactivated SARS-CoV-2 vaccine. *Cell Discov* **2022**, *8*, 10, doi:10.1038/s41421-022-00373-7.

560


561

## BBIBP-CorV vaccine group




## 3<sup>rd</sup> boost group

Total 144 BBIBP-CorV vaccinees






### AZD1222 (n=33)



### BNT162b2 (n=56)



### mRNA-1273 (n=55)

